China Insulin Market Review to 2018 – Increasing Focus on R&D Investments REQUEST FOR SAMPLE REPORT Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit China Insulin Market Review to 2018 – Increasing Focus on R&D Investments presents a comprehensive analysis of market size by volume and value of major types of insulin consumed in China. The report entails the segment wise market share analysis and company profiles of major players in the insulin market in China. The future analysis of the market has also been discussed in the report. The prevalence of diabetes in China has grown from 1% per capita in 1980 to more than 12% in 2013, making it the country with the most diabetic cases globally. In addition to 148 million people with pre-diabetes, 98.4 million people were diagnosed with diabetes in the country in 2013. In the near future, 6%-7% of those with pre-diabetes will be added to the existing diabetic population. Additionally, 40% of the youth aged 18-29 are potential diabetes patients with a high risk of stroke, heart disease and renal failure. Thus, the disease has become a matter of grave concern for the country and its wellbeing in the future. Diabetes has reached catastrophic levels in China. According to the International Diabetes Federation, 98.4 million people in China were diagnosed as diabetic in 2013, representing the country with the largest diabetes cases in the world. The undiagnosed diabetic cases in China amounted to ~ million in 2013. Adding significantly to the mortality rate of China, nearly ~ million people died from diabetes in the country during the same year. The consumption of insulin, the basis of diabetes care, is gaining momentum in China. With revenue generation of USD ~ million in 2013, China’s insulin market has grown at a tremendous pace since 2008. Although, low awareness relating to diabetes care in the country is a major cause hindering treatment and diagnosis of diabetes, the scenario is witnessing change. With a CAGR of ~% during 2008-2013, the demand for insulin has been underpinned by growing diabetic population, gradually increasing knowledge regarding diabetes care and the rising affluence of the masses. In terms of volume, it is estimated that nearly ~ thousand of million units (tMU) of insulin was consumed in 2013, which has been growing at ~% CAGR from 2008 to 2013. The insulin market in China is evolving rapidly. Analog insulin has become the preferred choice of the diabetic population in the country not only on account of efficacy, but also the fact that people are being able to afford the high costs that are carried with analog insulin replacement therapy. The market for human insulin in China is being substituted by analog insulin every year. In 2008, the Chinese insulin market was largely composed of human formulations with ~% share, which was reduced to ~% in 2013. The analog insulin market has grown considerably during the same period, registering an impressive CAGR of ~%. In 2013, the value addition to the overall insulin market by the sale of analog insulin was USD ~ million, whereas that of human insulin was USD ~ million. The government of China is actively involved in resisting the problems related to the increasing prevalence of diabetes in the country. Through the initiation of healthcare reforms, the government has significantly contributed to the growth of the insulin market in China. Medical insurance, drug supply security, medical-service provision and public health services are some of the initiatives undertaken by the government. The government has also collaborated with several leading insulin companies for spreading awareness via campaigns and free diagnostic services. The rising epidemic of diabetes in China and its economic wellbeing has attracted the major insulin enterprises operating globally. Companies such as Novo Nordisk, Eli Lilly and Sanofi Aventis capture a large proportion of the market, whereas domestic players including Tonghua Dongbao and Shanghai Fosun Pharmaceutical share a small fraction of the Chinese insulin market. Since analog insulin is emerging as the favored choice amongst the diabetic patients in the country, the vast and superior portfolio offered by the foreign multinationals has assisted them in constricting the market. These companies are also carrying out extensive R&D within the country in order to understand the local trends and supplying corresponding solutions. Key Topics Covered in the Report The market size of China insulin market in terms of value and volume Market segmentation by insulin replacement therapy and types of insulin Government regulation and support schemes for China’s insulin market Trends and developments in China insulin market Growth drivers of China insulin market Market share of major players in the insulin market in China Market share of major players by types of insulin Company profiles of major players in China’s insulin market Future outlook and projections of the insulin market in China Macroeconomic factors affecting the insulin market in China List of Tables: Table 1: Top 10 Countries with the Largest Diabetic Population Globally, 2013 Table 2: Asia Pacific Insulin Market Segmentation on the Basis of Revenue of Different Geographies in USD Million, 2008-2013 Table 3: Asia Pacific Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2013 Table 4: Asia Insulin Market Segmentation by Types of Insulin (Premix, Rapid Acting and Long Acting) on the Basis of Revenue in USD Million, 2013 Table 5: New Insulin Development by Major Insulin Companies Table 6: Mean Diabetes Related Expenditure Per Person with Diabetes in USD, 2012-2013 Table 7: SWOT Analysis of Asia Insulin Market Table 8: Asia Pacific Insulin Market Future Projection by Geography on the Basis of Revenue in USD Million, 2014-2018 Table 9: China Insulin Market Segmentation by Insulin Replacement Therapy (Human Insulin and Analog Insulin) on the Basis of Revenue in USD Million, 2008-2013 Table 10: China Insulin Market Segmentation by Type of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Consumption Volume in Thousand of Million Units (tMU), 2008-2013 Table 11: China Insulin Market Segmentation by Types of Insulin (Premix, Long Acting and Rapid Acting) on the Basis of Revenue in USD Million, 2008-2013 Table 12: China Insulin Market Segmentation by Type 1 and Type 2 Diabetes on the Basis of Revenue in USD Million, 2013 Table 13: Patent Expiry for Major Insulin Brands in China Table 14: Revenue of Major Companies in China Insulin Market in USD Million, 2013 Table 15: Market Share of Major Companies in China Insulin Market on the Basis of Volume in tMU, 2010-2013 Table 16: Revenue of Major Companies in China Human Insulin Market in USD Million, 2010 and 2013 Table 17: Revenue of Major Companies in China Analog Insulin Market in USD Million, 2010 and 2013 Table 18: Brand-wise Revenue of Major Companies in China Premix Insulin Market in USD Million, 2013 Table 19: Brand-wise Revenue of Major Long Acting Insulin Brands in China in USD Million, 2013 Table 20: Brand-wise Revenue of Major Rapid Acting Insulin Brands in China in USD Million, 2013 Table 21: Lantus Sales in China in USD Million, 2009-2013 Table 22: China Insulin Market Future Projections on the Basis of Revenue by Insulin Replacement Therapy in USD Million, 2014-2018 Table 23: China Insulin Market Future Projections on the Basis of Revenue by Insulin Type of Insulin in USD Million, 2014-2018 Table 24: Cause and Effect Relationship between the Dependent and Independent Variables Prevailing in India Insulin Market Table 25: Correlation Matrix of India Insulin Market Table 26: Regression Coefficients Output Browse and Download Report Here – http://www.kenresearch.com/healthcare/pharmaceutical-industry/china-insulin-market-research-report/574-91.html Contact: Ken Research Information Department info@kenresearch.com +91-011-47017199 Tags: Analog Insulin Market, China Insulin Industry, China Insulin Market Size, China Insulin Sector, Diabetes Insulin China, Human Insulin Market, Insulin Industry, Insulin Market, Insulin Novo Nordisk Market Share, Insulin Sector, Market Competition Insulin, Statistics Insulin Market, SWOT Insulin Market, Trends China Insulin, Type 1 Insulin Market